New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...

KAIST researchers have developed a way to reprogram immune cells already inside tumors into cancer-killing machines. A drug ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in ...

A giant functional atlas of immune cells in a Chinese cohort reveals crucial differences with European and Japanese data sets ...

Researchers have unlocked a way to grow the immune system’s “conductors” from stem cells, bringing ready-made cancer-fighting therapies a big step closer. For the first time, scientists at the Univers ...

aps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma ...

Researchers at WashU Medicine and their collaborators have created an immune cell atlas of multiple myeloma, a cancer of the ...

Scientists at the Icahn School of Medicine at Mount Sinai, in partnership with the Multiple Myeloma Research Foundation (MMRF ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Tumor immunotherapy has rapidly emerged as a cornerstone in oncology, revolutionizing the treatment landscape for patients with advanced malignancies.

Dr Anna Wilkins’ group is investigating how to target the tumour microenvironment of bladder and prostate cancer to prevent treatment resistance, especially to radiation given with curative intent.